Preclinical Atherosclerosis, Global Cardiovascular Risk and Cardiovascular Events

Author(s): S. Novo, G.R. Amoroso, F. Bonura, P. Carità, E. Corrado and G. Novo

DOI: 10.2174/978160805221911201010059

Download Download PDF Flyer Cite As
The Treatment of Patients with Preclinical Atherosclerosis: Beyond the Progetto Cuore’s Card of Risk

Pp: 59-62 (4)

Buy Chapters
Add to Cart

* (Excluding Mailing and Handling)

  • * (Excluding Mailing and Handling)

Abstract

SHS investigation development is considered from the geographical and historical viewpoint. 3 stages are described. Within Stage 1 the work was carried out in the Department of the Institute of Chemical Physics in Chernogolovka where the scientific discovery had been made. At Stage 2 the interest to SHS arose in different cities and towns of the former USSR. Within Stage 3 SHS entered the international scene. Now SHS processes and products are being studied in more than 50 countries.

Abstract

According to the Progetto Cuore, subjects with at least 2 or 3 RF are currently considered at intermediate risk. Recently, we demonstrated that the instrumental evidence of preclinical ATS (IMT/ACP) puts these patients into a higher category of risk. The consequent implications in clinical practice are very important: more aggressive pharmacological strategies could be useful, even if this recommendation is not yet unanimous. The inclusion of carotid IMT assessment in the "Progetto Cuore's" cards could provide further information for a better determination of GCVR and for a more aggressive pharmacological primary prevention.

Keywords:

Preclinical atherosclerosis, accurate GCVR stratification, clinical implications.

Recommended Chapters

We recommend

Favorable 70-S: Investigation Branching Arrow

Authors:Bentham Science Books

Cite as